🚨Rare cancer day is September 30th 👉Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers Molecular Cancer Therapeutics @RGroisberg OncoAlert mct.aacrjournals.org/content/17/7/1…

A fantastic #MDS21 MDS Foundation meeting has concluded. During meeting, we presented the design of a very important ongoing trial for #MDSsm on behalf of investigators. The VERONA trial is a pivotal registration-intent randomized Ph3 of AZA-Ven vs AZA+Placebo in higher risk MDS

🩺 Encouraging results from the recently published phase I of venetoclax + dara + dex in t(11;14) RRMM reignite the discussion on biomarker-driven treatment in multiple #myeloma. 📚 Read a summary here 👇 @BloodJournal IACH nizar jacques bahlis @kaufman_MMdoc loom.ly/G4fbqMQ

Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions [Sep 27, 2021] Orellana-Noia et al. @BloodJournal ow.ly/rfe750GhopT #lymsm #btsm

Outcome of pts with persistence MRD in NPM1m AML (n= 100) 👉🏾42% progression free at 1 yr: (1)30% Spontaneous CR with MRD -ve (2) 12% low level MRD 👉🏾 relapse assoc. with: (1)FLT3m (2)NPM MRD at end of treatment. #leusm #AML ⁦AML Hub⁩ ⁦Blood Advances⁩

We often criticize myeloma trials, but here’s a thread about some exciting trials that are currently active that I wanted to highlight. We can and should debate endpoints, but all arms get contemporary treatment and I’d gladly enroll a family member on them. Read on. #mmsm 🧵

#EHA has partnered with the EHA Scientific Working Group on Hematology and Aging to bring you the latest updates in geriatric #hematology research. Learn about unique treatment needs and options: eha.fyi/BCAM24

Join us Today for IACH webinar on Novel Therapeutic Approaches in BPDCN: Targeting CD123 and Beyond Thursday, September 30, 2021 7:00pm (Paris), 6:00pm (London), 1:00pm (New York), 10:00am (Los Angeles) Free Registration: us06web.zoom.us/webinar/regist… Naveen Pemmaraju, MD

Excellent presentation by Naveen Pemmaraju, MD at IACH on novel therapeutic approaches in #BPDCN. Few highlights below👇

For pts with #MPN, especially when #ruxolitinib under-performs/fails, more tx options are urgently needed. Enter: AXL inhibition. Read the full study 👉 bit.ly/2XKG1gf

👉🏾 Clonal neutropenia with CHIP inc. risk for hem malignancies. ashpublications.org/blood/article/…

In a single-arm, multicentre, ph 1 study, venetoclax with dose-adjusted EPOCH-R had acceptable safety and encouraging activity in patients with aggressive B-cell lymphoma. #lymsm thelancet.com/journals/lanha…

Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) #lymphoma #lymsm pubmed.ncbi.nlm.nih.gov/34629467/?utm_…

The death of Colin Powell, a fully vaccinated immunocompromised patient with cancer, underscores how dangerous the COVID anti-vaxx/anti-mask propaganda is. It also shows the hypocrisy of banning of mandates by some governors. How about the freedom of patients like Colin Powell?

The ability of metronidazole to cause neurotoxicity is not widely appreciated. Here's our quick overview led by Danica Quickfall, just out in CMAJ. cmaj.ca/content/193/42…

New article: Anti-BCMA Immuno-nanoPET Radiotracers for Improved Detection of Multiple Myeloma link.paperbirds.me/SBVZlN #MMSM #MultipleMyeloma #hematology

Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma frontiersin.org/article/10.338… #CART #bmtsm #CARTcell #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy ASTCT

Great review: RCHOP vs DA-EPOCH-R!

You'll always remember the day that you almost caught Captain Jack Sawyer

GOOD MORNING AMERICA ☕️